HUTCHMED Presents Strong Phase III Data for Sovleplenib in wAIHA at EHA, Reinforcing China NDA Priority Review
HCM is trading near its 52-week low of $10.4 (2.6% above the low).
Summary
HUTCHMED announced positive Phase III data for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA), showing significant efficacy and a favorable safety profile, which supports its NDA under priority review in China.
Key Events · Product Development and Regulatory · HCM
-
Positive Phase III Data Presented
HUTCHMED highlighted strong Phase III ESLIM-02 study data for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA) at the European Hematology Association (EHA) 2026 Congress.
-
Significant Efficacy Demonstrated
The study met its primary endpoint, showing a significantly higher durable response rate (66% vs 15%, p<0.0001) for sovleplenib compared to placebo. It also demonstrated superior overall response rate (70% vs 22%), reduced need for rescue therapy, and fewer blood transfusions.
-
Favorable Safety Profile
Sovleplenib exhibited a favorable safety profile, with no treatment-emergent adverse event (TEAE)-related deaths or discontinuations reported in the treatment group.
-
Advanced Regulatory Status in China
The New Drug Application (NDA) for sovleplenib in wAIHA was accepted for review and granted priority review by the China NMPA in April 2026, following Breakthrough Therapy Designation in March 2026. This data presentation further supports the ongoing review.
Analysis · HCM · Life Sciences
This filing details robust positive Phase III clinical trial data for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA), which was presented at a major hematology congress. The drug demonstrated significantly superior efficacy and a favorable safety profile, addressing a critical unmet need in a treatment landscape lacking targeted therapies. This strong data underpins the New Drug Application (NDA) that was already accepted for priority review by China's NMPA in April 2026, and the Breakthrough Therapy Designation received in March 2026. The detailed positive results further de-risk the drug's path to market in China and could provide a significant boost to the company, especially as its stock is currently trading near 52-week lows.
At the time of this filing, HCM was trading at $10.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $10.40 to $19.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.